Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study
出版年份 2021 全文链接
标题
Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study
作者
关键词
-
出版物
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 66, Issue 1, Pages -
出版商
American Society for Microbiology
发表日期
2021-10-26
DOI
10.1128/aac.01645-21
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study
- (2021) Mark Underwood et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A comparison of plasma efavirenz and tenofovir, dried blood spot tenofovir-diphosphate, and self-reported adherence to predict virologic suppression among South African women
- (2019) Tamsin K. Phillips et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Measuring adherence to antiretroviral therapy via hair concentrations in India
- (2019) Monica Gandhi et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A systematic review of the genetic mechanisms of dolutegravir resistance
- (2019) Soo-Yon Rhee et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial
- (2018) Sharon Nachman et al. Lancet HIV
- Cryo-EM structures and atomic model of the HIV-1 strand transfer complex intasome
- (2017) Dario Oliveira Passos et al. SCIENCE
- W-IQ-TREE: a fast online phylogenetic tool for maximum likelihood analysis
- (2016) Jana Trifinopoulos et al. NUCLEIC ACIDS RESEARCH
- Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents
- (2015) Rolando M. Viani et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age
- (2015) S. Nachman et al. Journal of the Pediatric Infectious Diseases Society
- Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV Integrase
- (2015) Peter K. Quashie et al. JOURNAL OF VIROLOGY
- The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness
- (2014) Melissa Wares et al. Retrovirology
- Biochemical Analysis of the Role of G118R-Linked Dolutegravir Drug Resistance Substitutions in HIV-1 Integrase
- (2013) Peter K. Quashie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics, Safety, and 48-Week Efficacy of Oral Raltegravir in HIV-1-Infected Children Aged 2 Through 18 Years
- (2013) S. Nachman et al. CLINICAL INFECTIOUS DISEASES
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
- (2013) Pedro Cahn et al. LANCET
- Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
- (2013) François Raffi et al. LANCET INFECTIOUS DISEASES
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
- (2013) Sharon L. Walmsley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing Regimens
- (2012) Carolina Garrido et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Barriers to Medication Adherence in HIV-Infected Children and Youth Based on Self- and Caregiver Report
- (2012) A. L. Buchanan et al. PEDIATRICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started